Clinical Trial Update: Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus [Phase 1]

View source ↗

Summary

Phase 1 study of selinexor in combination with irinotecan for gastric and distal esophageal adenocarcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Selinexor (selinexor)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Esophageal Cancer, Gastric Cancer | Phase 1 | Status: TERMINATED